Evidence map›Paper›PMID 29547897›Full record

ArticleAmerican journal of clinical pathology2018

Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin.

Amaris Castanon, Grant Pierre, Rohan Willis, E Nigel Harris, Elizabeth Papalardo, Zurina Romay-Penabad, Alvaro Schleh, Praveen Jajoria, Monica Smikle, Karel DeCeulaer and 7 more

Abstract readComparative StudyEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of clinical pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Amaris CastanonRheumatology/Internal Medicine, University of Texas Medical Branch, Galveston.
Grant PierreRheumatology/Internal Medicine, University of Texas Medical Branch, Galveston.
Rohan WillisRheumatology/Internal Medicine, University of Texas Medical Branch, Galveston.
E Nigel HarrisUniversity of the West Indies, Mona Campus, Kingston, Jamaica.
Elizabeth PapalardoRheumatology/Internal Medicine, University of Texas Medical Branch, Galveston.
Zurina Romay-PenabadRheumatology/Internal Medicine, University of Texas Medical Branch, Galveston.
Alvaro SchlehRheumatology/Internal Medicine, University of Texas Medical Branch, Galveston.
Praveen JajoriaPinnacle Health Rheumatology, Lemoyne, PA.
Monica SmikleUniversity of the West Indies, Mona Campus, Kingston, Jamaica.
Karel DeCeulaerUniversity of the West Indies, Mona Campus, Kingston, Jamaica.
Anne TeboARUP Institute of Clinical and Experimental Pathology, Salt Lake City, UT.
Troy JaskowskiARUP Institute of Clinical and Experimental Pathology, Salt Lake City, UT.
Marta M GuerraRheumatology, Hospital for Special Surgery, New York.
D Ware BranchMaternal Fetal Medicine, University of Utah and Intermountain Healthcare, Salt Lake City.
Jane E SalmonRheumatology, Hospital for Special Surgery, New York.
Michelle PetriRheumatology, Johns Hopkins University, Baltimore, MD.
Emilio B GonzalezRheumatology/Internal Medicine, University of Texas Medical Branch, Galveston.

Funding

Lupus CohortR01AR043727 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 1997 to 2015
$8.2M
Hopkins Lupus CohortR01AR069572 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2016 to 2020
$3.4M
Antiphospholipid antibodies and lupus: new molecular targets for treatmentR01AR056745 · NIAMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R., GONZALEZ, EMILIO B · 2010 to 2014
$1.6M
NIAMS NIH HHS R01 AR043727NIAMS NIH HHS R01 AR056745NIAMS NIH HHS R01 AR069572
6 · The paper itself

Abstract

objectivesWe evaluate the performance characteristics of antiphosphatidylserine (anti-PS), antiphosphatidylinositol (anti-PI), and antiphospholipid mixture (APhL) enzyme-linked immunosorbent assays (ELISAs) compared with anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) in a large group of patients with antiphospholipid (aPL)-related diseases.

methodsSerum samples from 548 patients from the Hopkins and Jamaican systemic lupus erythematosus cohorts, the PROMISSE cohort, and the Antiphospholipid Standardization Laboratory were examined for immunoglobulin G (IgG)/immunoglobulin M (IgM) positivity in aCL, anti-β2GPI, anti-PS, anti-PI, and APhL ELISA assays.

resultsAll IgG assays were associated with one or more thrombotic and/or obstetric manifestations, with an increased risk associated with higher antibody titers. Analytical performance was similar among assays, but IgG assays performed better than IgM counterparts.

conclusionsIncreasing titers of APhL, anti-PS, and anti-PI antibodies could indicate an increased risk of thrombotic and/or obstetric aPL-related manifestations. These assays may be promising biomarkers for particular APS manifestations.

Indexed as

AdultAntibodies, Antiphospholipidbeta 2-Glycoprotein IBiomarkersCardiolipinsCohort StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GImmunoglobulin MLupus Erythematosus, SystemicMaleMiddle AgedPhospholipidsThrombosisAntibodies, Antiphospholipidbeta 2-Glycoprotein IBiomarkersCardiolipinsImmunoglobulin GImmunoglobulin MPhospholipids

Identifiers

PMID29547897
PMCPMC5889035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.